Compare ADTX & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTX | DRCT |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 641.6K | 532.4K |
| IPO Year | 2020 | 2021 |
| Metric | ADTX | DRCT |
|---|---|---|
| Price | $1.37 | $3.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.8M | 272.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,195.00 | ★ $34,694,000.00 |
| Revenue This Year | N/A | $5.42 |
| Revenue Next Year | N/A | $9.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.05 | $0.04 |
| 52 Week High | $7.13 | $7.21 |
| Indicator | ADTX | DRCT |
|---|---|---|
| Relative Strength Index (RSI) | 72.92 | 54.84 |
| Support Level | $0.80 | $0.38 |
| Resistance Level | $1.84 | $6.04 |
| Average True Range (ATR) | 0.10 | 0.83 |
| MACD | 0.19 | -0.14 |
| Stochastic Oscillator | 70.65 | 12.14 |
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.